News

Press Releases

April 10, 2019

NodThera Highlights Significant Progress with Advancement of Lead Development Candidate and Key Additions to Board

– Company advances NT-0167 as first development candidate from a broad platform of NLRP3 inflammasome inhibitors –…

Read more >

October 23, 2018

NodThera announces the appointment of Alison Strutt PhD as Head of Finance & Operations, the launch of its new corporate office in Boston and the opening of its laboratory in Seattle

– Expansion in the US is consistent with NodThera’s strategy to access world class talent, foster collaborative…

Read more >

September 23, 2018

NodThera announces the appointment of Adam Keeney PhD as President and Chief Executive Officer

– Dr Keeney joins NodThera with over 20 years of pharmaceutical industry experience, including most recently at…

Read more >

April 10, 2019

NodThera Highlights Significant Progress with Advancement of Lead Development Candidate and Key Additions to Board

– Company advances NT-0167 as first development candidate from a broad platform of NLRP3 inflammasome inhibitors –…

Read more >

October 23, 2018

NodThera announces the appointment of Alison Strutt PhD as Head of Finance & Operations, the launch of its new corporate office in Boston and the opening of its laboratory in Seattle

– Expansion in the US is consistent with NodThera’s strategy to access world class talent, foster collaborative…

Read more >

September 23, 2018

NodThera announces the appointment of Adam Keeney PhD as President and Chief Executive Officer

– Dr Keeney joins NodThera with over 20 years of pharmaceutical industry experience, including most recently at…

Read more >

June 25, 2018

NodThera secures £28 million ($40 million) Series A Financing

– NodThera discovers and develops next generation NLRP3 inflammasome inhibitors for the treatment of diseases driven by…

Read more >

July 28, 2016

Epidarex Capital Creates Nodthera Limited

A pioneering new company based on Selvita research and utilizing novel immunological approaches to disease Edinburgh, Scotland,…

Read more >

Media Contact

Max Stendahl
Ten Bridge Communications
max@tenbridgecommunications.com
(508) 277-8117

For all other company inquiries, contact us at info@nodthera.com.